This retrospective observational study reviewed electronic medical records for all patients with lung cancer diagnosed at King Hussein Cancer Center from January 1, 2017, to April 1, 2024. Included ...

Real-world incidence and clinical outcomes of trastuzumab/pertuzumab-induced thrombocytopenia in adjuvant HER2-positive breast cancer: 8-year retrospective ...

Programmed death ligand 1 (PD-L1) immunohistochemistry has become a cornerstone in the diagnostic pathway of non-small cell lung cancer (NSCLC), guiding the use of anti-PD-1/PD-L1 therapies. By ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.

NEWARK, Del., June 16, 2026 /PRNewswire/ -- The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...

Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD. Patients with lower socioeconomic status were ...